Pasar al contenido principal

Targeting the tumor microenvironment to improve CAR-T cell based immunotherapy in pancreatic cancer

PLEC2021-008094

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i en Líneas Estratégicas
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION MEDICA APLICADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas

  • Justicia-Lirio, Pedro
  • Tristán-Manzano, María|||0000-0001-8721-1414
  • Maldonado-Pérez, Noelia|||0000-0001-5975-0488
  • Barbero-Jiménez, Carmen
  • Cortijo-Gutiérrez, Marina|||0000-0002-0161-515X
  • Pavlovic, Kristina
  • Molina-Estevez, Francisco J.
  • Muñoz, Pilar
  • Hinckley-Boned, Ana
  • Rodriguez-Madoz, Juan Roberto|||0000-0003-4327-1866
  • Prosper, Felipe|||0000-0001-6115-8790
  • Griñán-Lison, Carmen
  • Navarro-Marchal, Saúl Abenhamar|||0000-0003-3508-6396
  • Panisello, Carla|||0000-0002-8437-4418
  • Muñoz-Ballester, Julia
  • González-Sierra, Pedro A.
  • Herrera, Concha
  • Marchal, Juan A.
  • Martín, Francisco|||0000-0003-1961-8612
Although chimeric antigen receptor (CAR) T cell therapy has revolutionized type B cancer treatment, efficacy remains limited in various lymphomas and solid tumors. Reinforcing conventional CAR-T cells to release cytokines can improve their efficacy but also increase safety concerns. Several strategies have been developed to regulate their secretion using minimal promoters that are controlled by chimeric proteins harboring transactivators. However, these chimeric proteins can disrupt the normal physiology of T cells. Here, we present the first transactivator-free anti-CD19 CAR-T cells able to control IL-18 expression (iTRUCK19.18) under ultra-low doses of doxycycline and without altering cellular fitness. Interestingly, IL-18 secretion requires T cell activation in addition to doxycycline, allowing the external regulation of CAR-T cell potency. This effect was translated into an increased CAR-T cell antitumor activity against aggressive hematologic and solid tumor models. In a clinically relevant context, we generated patient-derived iTRUCK19.18 cells capable of eradicating primary B cells tumors in a doxycycline-dependent manner. Furthermore, IL-18-releasing CAR-T cells polarized pro-tumoral macrophages toward an antitumoral phenotype, suggesting potential for modulating the tumor microenvironment. In summary, we showed that our platform can generate exogenously controlled CAR-T cells with enhanced potency and in the absence of transactivators.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

  • Larrayoz, Marta
  • García-Barcina, María
  • Celay, Jon
  • Etxebeste, Amaia
  • Jimenez, Maddalen
  • Perez, Cristina
  • Ordoñez, Raquel
  • Cobaleda, Cesar
  • Botta, Cirino
  • Fresquet, Vicente
  • Roa, Sergio
  • Goicoechea, Ibai
  • Maia, Catarina
  • Lasaga, Miren
  • Chesi, Marta
  • Bergsagel, P Leif
  • Larrayoz, Maria J
  • Calasanz, Maria J
  • Campos-Sanchez, Elena
  • Martinez-Cano, Jorge
  • Panizo, Carlos
  • Rodriguez-Otero, Paula
  • Vicent, Silvestre
  • Roncador, Giovanna
  • Gonzalez, Patricia
  • Takahashi, Satoru
  • Katz, Samuel G
  • Walensky, Loren D
  • Ruppert, Shannon M
  • Lasater, Elisabeth A
  • Amann, Maria
  • Lozano, Teresa
  • Llopiz, Diana
  • Sarobe, Pablo
  • Lasarte, Juan J
  • Planell, Nuria
  • Gomez-Cabrero, David
  • Kudryashova, Olga
  • Kurilovich, Anna
  • Revuelta, Maria V
  • Cerchietti, Leandro
  • Agirre, Xabier
  • San Miguel, Jesus
  • Paiva, Bruno
  • Prosper, Felipe
  • Martinez-Climent, Jose A
The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry eight MM lesions (NF-κB, KRAS, MYC, TP53, BCL2, cyclin D1, MMSET/NSD2 and c-MAF) combinatorially activated in B lymphocytes following T cell-driven immunization. Fifteen genetically diverse models developed bone marrow (BM) tumors fulfilling MM pathogenesis. Integrative analyses of ∼500 mice and ∼1,000 patients revealed a common MAPK–MYC genetic pathway that accelerated time to progression from precursor states across genetically heterogeneous MM. MYC-dependent time to progression conditioned immune evasion mechanisms that remodeled the BM microenvironment differently. Rapid MYC-driven progressors exhibited a high number of activated/exhausted CD8 T cells with reduced immunosuppressive regulatory T (T) cells, while late MYC acquisition in slow progressors was associated with lower CD8 T cell infiltration and more abundant T cells. Single-cell transcriptomics and functional assays defined a high ratio of CD8 T cells versus T cells as a predictor of response to immune checkpoint blockade (ICB). In clinical series, high CD8 T/T cell ratios underlie early progression in untreated smoldering MM, and correlated with early relapse in newly diagnosed patients with MM under Len/Dex therap, This work was supported by the imCORE Network on behalf of F. Hoffmann-La Roche (NAV4 and NAV15 projects). Additional support was obtained from Spanish Ministry of Health - Instituto de Salud Carlos III (FIS), grants PI19/00818, PI20/00048, PI20/00260, CIBERONC no. CB16/12/00489 and no. CB16/12/00369, with support from FEDER (Fondo Europeo de Desarrollo Regional); Paula and Rodger Riney Foundation; Accelerator Award Program from the Spanish Association Against Cancer (AECC), Cancer Research United Kingdom (CRUK), and Associazione Italiana per la Ricerca sul Cancro (AIRC); Spanish Ministry of Education and Science, grants SAF2017-83061-R, PLEC2021-008094, and PID2021-128283OA; Fundacion Arnal Planelles; Fundacion Ramon Areces; Banco de Santander; European Research Council Starting Grant (MYELOMANEXT); CRIS Cancer Foundation (PR_EX_2020-02); AICR grant 24534, 2021; and Leukemia Lymphoma Society. M.C. and P.L.B. were supported by RO1 CA234181. L.C. was supported by R01 CA242069. M.L. was supported by a junior investigator grant from AECC. M.J.G.-B. was supported by Fundacion Arnal Planelles. J.C. was supported by AECC through the ‘Accelerator’ Award. S.R. was supported by RYC-2014-16399/MEC. J.M.C. is the recipient of an FPU fellowship from Universidad Autonoma de Madrid.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Donor insertion into CX3CR1 allows epigenetic modulation of a constitutive promoter on hematopoietic stem cells and its activation upon myeloid differentiation

  • Ramos-Hernández, Iris
  • Fuster-García, Carla
  • Aguilar-González, Araceli
  • Lozano-Vinagre, María L.
  • Guenechea-Amurrio, Guillermo
  • Sánchez-Luque, Francisco J.
  • Gonçalves, Manuel A. F. V.
  • Cathomen, Toni
  • Muñoz, P.
  • Molina-Estévez, Francisco J.
  • Martín, Francisco
To improve ex vivo gene therapy strategies involving hematopoietic stem and progenitor cells (HSPCs), we propose a novel knock-in strategy (named KI-Ep) aiming to achieve transgene regulation of the inserted cassette through the acquisition of naturally occurring epigenetic marks. Based on this hypothesis, we selected CX3CR1 (a myeloid-specific gene presenting a poised histone signature on primitive HSPCs) as safe harbor to generate KI-Ep HSPCs. We demonstrated that, unlike the expression pattern achieved with lentiviral vectors (LVs), the insertion of a constitutive expression cassette into the intron 1 of the CX3CR1 locus (CX3CR1-I) in HSPCs resulted in very low expression levels in the more primitive HSPCs but, crucially, strong expression in HSPC-differentiated populations (especially myeloid cells), both in vitro and in vivo. Furthermore, we showed that the promoter of the expression cassette inserted into CX3CR1-I acquired epigenetic marks associated with poised genes during the HSPC stage. These marks transitioned to activated histone states upon KI-Ep HSPCs differentiation. In summary, here, we introduce the KI-Ep concept which enables the epigenetic modulation of the inserted transgene during the HSPCs stem cell stages and its subsequent activation upon differentiation., This work was supported by the by the Fondo Europeo de Desarrollo Regional (FEDER), NextGenerationEU funds—actions of the Recovery and Resilience Mechanism and the Instituto de Salud Carlos III (ISCIII) through the financing research projects [PI18/00337 and PI21/00298 to F.M., and PI21/00875 to P.M.], networks (RICORS-TerAv [RD21/ 0017/0004 to F.M., P.M. and F-J.M-E.; RD21/0017/0027 to G.G-A.] and personal (FI19/00163 to I.R-H.). By the Consejería de Salud y Familias (Junta de Andalucía), under the 2019 call for “Proyectos Estratégicos I + D + I con incorporación de capital humano” [PEER-0286-2019 to P.M.] and FEDER/European Cohesion Fund (FSE) for Andalucía [PECART-0031-2020 to F.M.]; by the Consejería de Transformación Económica, Industria, Conocimiento y Universidades (Junta de Andalucía) through the EMERGIA EMERGIA2020 programe [EMERGIA20_00049 to P.M.]. By the Pompe Competitive Research Grant Program by SPARK Therapeutics [SPARK-2022-002 to F-J.M-E.]; by the Ministerio de Ciencia, Innovación y Universidades [PID2021-125077OB-C22 to G.G-A]; the Ministerio de Ciencia e innovación (MICIN)—líneas estratégicas [PLEC2021-008094 to F.M.] by Ministerio de Ciencia e innovación (MICIN), Plan de Recuperación, transformación y resilencia, Centro para el Desarrollo Tecnológico Industrial (CDTI) and European Union-Next Generation EU [00123009/SNEO-20191072 and PMPTA22/00060 to F.M.]; by the Spanish National Research Agency [AEI; grants RYC2021-031920-I and CNS2022-136033 to F-J.S-L.]. And by the European Union, Horizon Europe Framework Program through the EIC PathfinderChallenges [X-PAND 101070950 to T.C] and the European Cooperation in Science and Technology (COST) [GeneHumdi-CA21113]. Funding to pay the Open Access publication charges for this article was provided by Instituto de Salud Carlos III (ISCIII) [RD21/ 0017/0004]; Universidad de Granada/CBUA., Peer reviewed